Haemodialysis with Tinzaparin Versus Dialysate Citrate as Anticoagulation

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Anticoagulation with citrate-containing haemodialysate (cHD) is an alternative to tinzaparin haemodialysate (tHD). The study investigated whether cHD would differ when changed from tHD. The same 18 patients were their own controls followed up with cHD for 5 months. LDL-cholesterol decreased at the end of a cHD session ( p = 0.01). Neutrophils ( p = 0.013) and monocytes ( p = 0.007) dropped more during a cHD session. During the follow-up period of cHD, approximately 50% needed additional tinzaparin. Before the cHD session could start, there was a lower total cholesterol at 2 weeks ( p = 0.014) and LDL-cholesterol at 1 month ( p = 0.011) versus an increase of LDL at 5 months ( p = 0.02). Only patients without additional tinzaparin had a reduction of C-reactive protein (CRP) at 2 months of cHD ( p < 0.05) but not later. Solely cHD seems possible only in half of the patients. A greater reduction in granulocytes and monocytes during cHD indicates a more extensive blood membrane interaction, while CRP may be lower.

Related collections

Author and article information

Journal

Journal ID (publisher-id): BPU

Journal ID (nlm-ta): Blood Purif

Journal ID (doi): 10.1159/issn.0253-5068

Title: Blood Purification

Publisher: S. Karger AG

ISSN (Print): 0253-5068

ISSN (Electronic): 1421-9735

Publication date Subscription-year: 2018

Publication date (Print): July 2018

Publication date (Electronic): 04 July 2018

Volume: 46

Issue: 3

Pages: 257-263

Affiliations

Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden

Author notes

*Dr. Dana Mahmood, Department of Public Health and Clinical Medicine, Umea University, Östersunds sjukhus, Stenåldersvägen 36, Östersund, SE–831 83 Umea (Sweden), E-Mail dana.mahmood@regionjh.se

Article

Publisher ID: 490409 Other ID: Blood Purif 2018;46:257–263

DOI: 10.1159/000490409

PubMed ID: 29972824

SO-VID: cff11c68-a69f-4e6d-8ff3-943963de5427

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 19 September 2017

Date accepted : 28 May 2018

Page count

Tables: 4, Pages: 6

Comments

Comment on this article

scite_

Cited by 2

See all cited by

Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

Submit here before July 31, 2024